Breaking News
Home / Business News (page 2)

Business News

Roche Enters License and Collaboration Agreement with ImaginAb for its CD8 Imaging Agent

LOS ANGELES, July 9, 2019 /PRNewswire/ — ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced today that it has entered into a non-exclusive license and collaboration agreement with Roche. Under the terms of the agreement, Roche will use ImaginAb’s novel minibody CD8 T cell imaging agent in immuno-oncology clinical …

Read More »

Gilead Partners with Lyndra Therapeutics for the Development of Ultra-Long-Acting HIV Therapies

WATERTOWN, Mass.–(BUSINESS WIRE)–Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies. Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV. Lyndra’s ultra-long-acting dosage form has …

Read More »

Skyhawk Therapeutics Enters Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

WALTHAM, Mass., July 8, 2019 /PRNewswire/ — Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered a strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize small molecules that modulate RNA splicing.  Skyhawk’s proprietary SkySTAR™ technology platform will be employed …

Read More »

Skyhawk Therapeutics and Biogen Expand Collaboration Agreement for Development of Small Molecule RNA Splicing Modifiers

WALTHAM, Mass., July 8, 2019 /PRNewswire/ — Skyhawk Therapeutics, Inc. (“Skyhawk”) today announced the expansion of its collaboration with Biogen, originally announced January 4, 2019.  The expansion, which capitalizes on the breadth of Skyhawk’s SkySTAR™ technology platform, extends Biogen’s exclusive license to worldwide intellectual property rights beyond the original collaboration’s …

Read More »

Hologic Makes a Binding Offer to Acquire French-Based Ultrasound Innovator SuperSonic Imagine

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has made a binding offer to acquire (directly or through an affiliate) SuperSonic Imagine (Euronext: SSI, FR0010526814), a France-based innovator in cart-based ultrasound products, and that it has entered into an exclusive negotiation agreement …

Read More »

Janssen Collaborates with UC Berkeley and UCSF to Expand Data Science Research in Healthcare

SAN FRANCISCO–(BUSINESS WIRE)–Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced a collaboration with the University of California, Berkeley (UC Berkeley) and the University of California, San Francisco (UCSF), with the goal of inspiring data-driven approaches to improve health and develop …

Read More »

Amgen And The Institute For Protein Design at University of Washington Partner to Test New Technologies and Create Protein-Building Approaches for New Medicines

THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) and the University of Washington’s Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building …

Read More »

Gilead Enters $2.4 Billion Deal with Nurix for Development of Innovative Targeted Protein Degradation Drugs

FOSTER CITY, Calif. & SAN FRANCISCO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients …

Read More »

Catalent to Buy Bristol-Myers Squibb’s Manufacturing Facility in Italy

NEW YORK & SOMERSET, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Catalent, Inc. (NYSE: CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies,development and manufacturing solutions for drugs, …

Read More »

Ultragenyx and Arcturus Expand Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

NOVATO, Calif. and SAN DIEGO, June 19, 2019 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading messenger RNA medicines company, today announced that they …

Read More »